Minerva Neurosciences (NERV) Q2 2024 earnings summary

Executive summary

• Net loss for Q2 2024 was $8.2 million, compared to $6.2 million in Q2 2023, with continued engagement with the FDA to address the Complete Response Letter for roluperidone.

• Cash, cash equivalents, and restricted cash totaled $31.0 million at June 30, 2024, expected to fund operations for at least the next 12 months.

• The company has not generated revenue from product sales and continues to incur significant operating losses, with an accumulated deficit of $413.6 million as of June 30, 2024.

• Focus remains on CNS diseases, with lead candidate roluperidone for schizophrenia and exclusive rights to MIN-301 for Parkinson's disease.

Financial highlights

• Research and development expenses increased to $3.9 million in Q2 2024 from $1.9 million in Q2 2023, mainly due to higher subcontractor fees.

• General and administrative expenses decreased to $2.4 million in Q2 2024 from $2.6 million in Q2 2023, primarily due to lower compensation expenses.

• Non-cash interest expense for the sale of future royalties was $2.3 million in Q2 2024, up from $2.0 million in Q2 2023.

• Net loss per share was $(1.09) for Q2 2024; weighted average shares outstanding were 7.6 million.

• No revenue was recognized from product sales or royalties during the period.

Outlook and guidance

• Management expects continued operating losses and negative cash flows as clinical and regulatory activities for product candidates progress.

• Additional capital will be required to fund later-stage clinical development and potential commercialization; the company is exploring equity financings and other arrangements.

• Cash on hand is expected to meet operating commitments for at least the next 12 months, but future expenditures depend on clinical trial design, timing, and outcomes.

• Ongoing efforts to manage operating expenses and maintain sufficient liquidity.